Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Immunofluorescent staining of A549 (ATCC CCL-185) cells. Cells were seeded in a 96 well imaging plate (Cat. No. 353219) at ~ 10 000 cells per well. After overnight incubation, cells were stained using the alcohol perm protocol and the Mouse Anti-Calretinin antibody. The second step reagent was FITC goat anti mouse Ig (Cat. No. 554001). Images were taken on a BD Pathway™ 855 bioimaging system using a 20x objective. This antibody also stained HeLa (ATCC CCL-2) cells using the alcohol perm protocol and A549, HeLa and U-2 OS (ATCC HTB-96) cells using the Triton™ X-100 fix/perm protocol (see Recommended Assay Procedure).
Western blot analysis of Calretinin on a rat cerebrum lysate. Lane 1: 1:250, lane 2: 1:500, lane 3: 1:1000 dilution of the Mouse Anti-Calretinin antibody.
Immunofluorescent staining of A549 (ATCC CCL-185) cells. Cells were seeded in a 96 well imaging plate (Cat. No. 353219) at ~ 10 000 cells per well. After overnight incubation, cells were stained using the alcohol perm protocol and the Mouse Anti-Calretinin antibody. The second step reagent was FITC goat anti mouse Ig (Cat. No. 554001). Images were taken on a BD Pathway™ 855 bioimaging system using a 20x objective. This antibody also stained HeLa (ATCC CCL-2) cells using the alcohol perm protocol and A549, HeLa and U-2 OS (ATCC HTB-96) cells using the Triton™ X-100 fix/perm protocol (see Recommended Assay Procedure).
Western blot analysis of Calretinin on a rat cerebrum lysate. Lane 1: 1:250, lane 2: 1:500, lane 3: 1:1000 dilution of the Mouse Anti-Calretinin antibody.
Immunofluorescent staining of A549 (ATCC CCL-185) cells. Cells were seeded in a 96 well imaging plate (Cat. No. 353219) at ~ 10 000 cells per well. After overnight incubation, cells were stained using the alcohol perm protocol and the Mouse Anti-Calretinin antibody. The second step reagent was FITC goat anti mouse Ig (Cat. No. 554001). Images were taken on a BD Pathway™ 855 bioimaging system using a 20x objective. This antibody also stained HeLa (ATCC CCL-2) cells using the alcohol perm protocol and A549, HeLa and U-2 OS (ATCC HTB-96) cells using the Triton™ X-100 fix/perm protocol (see Recommended Assay Procedure).
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Bioimaging
1. Seed the cells in appropriate culture medium at ~10,000 cells per well in a BD Falcon™ 96-well Imaging Plate (Cat. No. 353219) and culture overnight.
2. Remove the culture medium from the wells, and fix the cells by adding 100 μl of BD Cytofix™ Fixation Buffer (Cat. No. 554655) to each well. Incubate for 10 minutes at room temperature (RT).
3. Remove the fixative from the wells, and permeabilize the cells using either BD Perm Buffer III, 90% methanol, or Triton™ X-100:
a. Add 100 μl of -20°C 90% methanol or Perm Buffer III (Cat. No. 558050) to each well and incubate for 5 minutes at RT.
OR
b. Add 100 μl of 0.1% Triton™ X-100 to each well and incubate for 5 minutes at RT.
4. Remove the permeabilization buffer, and wash the wells twice with 100 μl of 1× PBS.
5. Remove the PBS, and block the cells by adding 100 μl of BD Pharmingen™ Stain Buffer (FBS) (Cat. No. 554656) to each well. Incubate for 30 minutes at RT.
6. Remove the blocking buffer and add 50 μl of the optimally titrated primary antibody (diluted in Stain Buffer) to each well, and incubate for 1 hour at RT.
7. Remove the primary antibody, and wash the wells three times with 100 μl of 1× PBS.
8. Remove the PBS, and add the second step reagent at its optimally titrated concentration in 50 μl to each well, and incubate in the dark for 1 hour at RT.
9. Remove the second step reagent, and wash the wells three times with 100 μl of 1× PBS.
10. Remove the PBS, and counter-stain the nuclei by adding 200 μl per well of 2 μg/ml Hoechst 33342 (e.g., Sigma-Aldrich Cat. No. B2261) in 1× PBS to each well at least 15 minutes before imaging.
11. View and analyze the cells on an appropriate imaging instrument.
Bioimaging: For more detailed information please refer to http://www.bdbiosciences.com/support/resources/protocols/ceritifed_reagents.jsp
Western blot: For more detailed information please refer to http://www.bdbiosciences.com/support/resources/protocols/monoclonal_anti.jsp
A low level of intracellular free Ca2+ is essential for a variety of cellular functions and is mediated by the sequestration of Ca2+ in the ER, by the action of plasma membrane Ca2+ pumps, and by Ca2+ binding proteins. The Ca2+ binding protein, Calretinin, is a member of the calmodulin superfamily whose members promote calcium homeostasis by acting as buffers of intracellular free Ca2+. Although Calretinin is expressed in certain populations of neurons throughout the central and peripheral nervous systems, it is primarily expressed in the olfactory bulb and auditory pathways. Calretinin most closely resembles calbindin D28k, another member of the calmodulin family. These two proteins share 58% amino acid identity and contain six EF-hand Ca2+ binding motifs. Excess Calretinin or calbindin results in decreased transcription from PCE1, a calcium responsive element in the calmodulin II promoter. This supports the role of Calretinin as a regulator of intracellular free Ca2+ levels. Furthermore, truncated forms of Calretinin have been found in certain tumor cells, but are absent from normal cells which express wild type Calretinin. Thus, these isoforms may have a role in tumorigenesis.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.